Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study
Conditions
Human Immunodeficiency Virus (HIV)-1 Infection · HIV-1 Subtype A6 Infection · HIV-1 Subtype B Infection · Virologically Suppressed HIV-1 Infection Receiving Long-Acting Antiretroviral Therapy
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Hospital Na Bulovce Praque HIV Centre, Department of Infectious Diseases, Prague, Czechia
Contact: Principal Investigator (David Jilich, MD)MainFachArzt, Frankfurt, Germany
Contact: Principal Investigator (Pavel Khaykin, MD)Katedra Chorób Zakaźnych i Niedoborów Immunologicznych, Szczecin, West Pomeranian Voivodeship, Poland
Contact: Study coordinator (Miłosz Parczewski, prof. dr hab. n. med.) · klinzak@pum.edu.pl · +48 91 813 94 41Wojewódzki Szpital Obserwacyjno-Zakaźny, Bydgoszcz, Poland
Contact: Principal Investigator (Anita Olczak, dr hab. n. med.)Szpitale Pomorskie, Gdansk, Poland
Contact: Study coordinator (Maria Hlebowicz, Dr n.med.)Contact: Principal Investigator (Maria Hlebowicz, dr n. med.)Wojewódzki Szpital Zakaźny w Warszawie, Warsaw, Poland
Contact: Principal Investigator (Iwona Cielniak, dr n. med.)Wrocławskie Centrum Zdrowia, Wroclaw, Poland
Contact: Principal Investigator (Aleksandra Szymczak, dr n. med.)